ENZOLVE TECHNOLOGIES LIMITED

Enzolve Technologies Limited is an innovative, research‑driven company that harnesses the power of engineered enzymes to create specialised solutions for the healthcare, fine‑chemicals and life‑sciences sectors. Drawing on a strong intellectual property portfolio, Enzolve designs, manufactures and commercialises enzyme‑based platform technologies that address real‑world challenges, from clinical diagnostics to asymmetric synthesis.

Among its flagship offerings is the NeoScreenPak, a suite of tests that screen newborns for seven of the eleven most common inherited metabolic disorders, including a newly launched assay for phenylketonuria (PKU). The company also provides advanced protein‑visualisation reagents for electrophoresis, and offers expert contract‑research services to assist organisations with any enzyme‑related queries. Recent investment from Enterprise Ireland has enabled Enzolve to scale up production of its newborn‑screening kits for international markets, underscoring its commitment to improving health outcomes worldwide.